1Morel P;Revillard JP;Nicolas JF.Anti-CD4 monoclonal antibody therapy in severe psoriasis[J],1992.
2Gottlieb AB;Lebwohl M;Shirin S.Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot multicenter multiple-do se placebo-controlled study[J],2000.
3Oh C J;Das KM;Gottlieb AB.Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramat ically decreases the clinical activity of pso riasis lesions[J],2000(42).
4Kirby B;Marsland AM;Carmichael A J.Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate[J],2001.
5Ogilvie AL;Antoni C;Dechant C.Treatment of psoriatic arthritis with antitu mour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treat ment with methotrexate[J],2001.
6Chaudhari U;Romano P;Mulcahy LD.Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial,2001(9271).
7Mease PJ;Goffe BS;Metz J.Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial[J],2000.
8Yazici Y;Erkan D;Lockshin MD.A pre liminary study of etanercept in the treat ment of severe resistant psoriatic arthritis,2000.
9Zeltser R;Valle L;Tanck C.Clini cal histological and immunophenotypic characteristics of injection site reactions associated with etanercept:a recombinant tumor necrosis factor alpha receptor:Fc fusion protein,2001.
10Seifert M;Sterry W;Effenberger E.The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human ker atinocytes[J],2000(4).
